An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK.

Abstract

BACKGROUND AND PURPOSE Oltipraz, a cancer chemopreventive agent, has an anti-steatotic effect via liver X receptor-α (LXRα) inhibition. Here we have assessed the biological activity of a major metabolite of oltipraz (M2) against liver steatosis and steatohepatitis and the underlying mechanism(s). EXPERIMENTAL APPROACH Blood biochemistry and histopathology… (More)
DOI: 10.1111/bph.12057

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.